Stand Up To Cancer’s Post

This post by Stand Up To Cancer is a prime example of how to support employers and employees affected by cancer through innovative treatments like immunotherapy. Highlighting these groundbreaking advances showcases the power of research and collaboration in the fight against cancer. For our followers: consider incorporating initiatives that support cancer treatment advancements and employee well-being into your workplace. Providing access to the latest treatment information, supporting clinical trial participation, and fostering a culture of health awareness can make a significant difference. Our Tree of Life Employee Vitality and Cancer Defense Program is designed to support employees at every phase of their cancer journey—diagnosis, treatment, survivorship, caregiving, and preventative care. By integrating this comprehensive approach, employers can enhance the quality of life for their employees and create a supportive work environment. Kudos to Stand Up To Cancer for their incredible work in advancing immunotherapy. Let's continue to support our employees by embracing innovative treatments and fostering a culture of health and well-being. #ImmunotherapyAwarenessMonth #StandUpToCancer #CancerSupport #WorkplaceWellbeing #TreeOfLifeProgram

Retrospective pooled analysis examined the association between tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue and survival outcomes among 1966 patients diagnosed with early-stage triple-negative breast cancer (TNBC) who received locoregional therapy but no chemotherapy. Results revealed that higher TIL levels were significantly associated with improved invasive disease-free survival (iDFS), recurrence-free survival (RFS), survival free of distant recurrence (DRFS), and overall survival. Even after adjusting for various factors, including age, tumor size, nodal status, histological grade, and receipt of radiotherapy, each 10% higher TIL increment independently correlated with better survival outcomes. These findings underscore the prognostic significance of TIL abundance in breast cancer tissue for patients with early-stage TNBC who did not undergo chemotherapy, suggesting its potential as a valuable prognostic factor in clinical decision-making. Source: JAMA Network (Link to article in comments) Roberto Leon-Ferre Roberto Salgado

Breakthrough Therapy Eradicated Colorectal Cancer in All Patients: In a clinical trial involving 14 participants, immunotherapy on its own effectively eradicated rectal cancer. The trial reported a complete remission in all participants, as the cancer entirely vanished and has remained absent in all patients, some of whom have been cancer-free for as long as two years. The patients in the trial had tumors with a specific genetic makeup known as mismatch repair-deficient (MMRd) or microsatellite instability (MSI). MMRd tumors develop a defect in their ability to repair certain types of mutations that occur in cells. When those mutations accumulate in the tumor, they stimulate the immune system, which attacks the mutation-ridden cancer cells. All patients received treatment with a checkpoint inhibitor, a type of immunotherapy that blocks the PD-1 protein on T-cells, allowing the immune system to attack the cancer. No patients received any other standard treatments for rectal cancer, such as radiation or surgery. #cancer #oncology #colorectalcancer #immunotherapy #drugdiscovery #drugdelivery #medicalsciences #pharmaceutics #medicine #research #immunooncology Scott Kopetz

A groundbreaking investigator-initiated trial conducted at NewYork-Presbyterian/Weill Cornell Medicine has revealed promising results regarding neoadjuvant immunotherapy's efficacy in treating resectable colorectal cancer, historically deemed ineffective for most patients. While immunotherapy has shown remarkable responses in a small subset of patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer, the majority with mismatch repair proficient/microsatellite stable (pMMR/MSS) tumors lack effective treatment options. The NEST-1 clinical trial, led by Dr. Pashtoon Kasi, investigated neoadjuvant treatment with botensilimab (BOT) and balstilimab (BAL) in a diverse patient cohort, challenging the conventional surgery-then-chemotherapy paradigm. Despite recruitment challenges, the trial demonstrated significant potential, emphasizing the importance of multidisciplinary approaches and innovative treatment strategies in advancing care for colorectal cancer patients. Source: New York Presbyterian https://lnkd.in/df4rR-iA Pashtoon Kasi

Finally, it's here!! After over thirty years of anticipation, the FDA has finally given approval for lifileucel (Amtagvi), marking a significant milestone as the first cancer therapy to harness tumor-infiltrating lymphocytes (TILs) for treatment. The FDA announced the approval of lifileucel, marking a breakthrough as the first cellular therapy sanctioned for treating solid tumors, specifically the skin cancer melanoma. The approval of lifileucel stems from results in a clinical trial sponsored by Iovance Biotherapeutics. Among the 70+ participants receiving the FDA-approved lifileucel dosage, nearly one-third experienced some tumor size reduction (tumor response), with complete tumor disappearance (complete response) observed in several cases. Additionally, approximately 40% of patients whose cancers responded to lifileucel showed no cancer progression one year post-treatment. #fda #lifileucel #lifileucelapproval #cancertherapy #lovancebiotherapeutics #amtagvi #cancer #nci #myoclinic #melanoma

😆 Exciting news! --- 📚 The latest Mini Review from ETAT Journal is now available online! 📄 Titled "Management of stage III non-small-cell lung cancer: rays of hope". This insightful piece by Floryane Kim, Maxime Borgeaud, Alfredo Addeo and Alex Friedlaender* 📩  This review describes the current landscape of management of stage III NSCLC, discussing the critical issue of resectability, and highlighting the recent advancements in the field, particularly the incorporation of immune-checkpoint inhibitors (ICIs) and targeted therapies in this setting. 📍 Access the full text at: https://lnkd.in/gpNcNfH5 🔓 The PDF version is also available for download: https://lnkd.in/g4J6Hdxd   💯 Don't miss out on this exciting opportunity to expand your knowledge and stay up-to-date with the latest developments.   ❗ Happy reading! Non-small-cell lung cancer #NSCLC, #stageIII, #PerioperativeImmunotherapy, #TargetedTherapy, #Chemo-radiotherapy, #MultidisciplinaryManagement

⚡ FluoGuide A/S selects laser system for photothermal cancer therapy with FG001 FluoGuide A/S’s lead product, FG001 fluoresces and is designed to bind urokinase-type plasminogen activator receptor (uPAR) making it specific to cancer and with a potential for most patients with solid cancer. Clinical data have demonstrated FG001’s efficacy in guiding surgeries for three cancer indications: aggressive brain cancer, head and neck cancer, and lung cancer. In addition to providing visual guidance for surgeons during removal of cancer cells, FG001 also has photothermal therapy (PTT) properties. This therapeutic potential of FG001 is to kill cancer cells using near-infrared light, holding potential to significantly enhance outcomes for cancer patients. “We have now selected the laser system to support the further development of FG001 as photothermal cancer therapy. An application, which holds considerable potential for improving cancer treatment and outcomes for patients,” says Morten Albrechtsen, CEO of FluoGuide A/S. Read more online: https://lnkd.in/e3uVKSQ3 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

As we understand more about the molecular drivers of #cancer, it is time for us to move away from classifying tumors by tissue of origin, a notion with the potential to transform patient care and improve outcomes. https://lnkd.in/gg4WUtFS

Future is now

Do you know that #Immunotherapy is one of the most promising treatments for lung cancer? It has become increasingly popular in recent years due to its effectiveness and fewer side effects compared to chemotherapy. Immunotherapy works by using drugs designed to help your body’s own immune system fight cancer more effectively. These therapies work by either boosting the immune response, such as T-cell therapy, or blocking certain molecules that prevent the immune system from attacking tumor cells. It can also be used in combination with other treatments like surgery, chemo, and radiation therapy. The key benefit of immunotherapy over traditional cancer treatments is that it targets only the tumor cells while leaving healthy cells untouched — meaning there are fewer side effects than with chemo or radiation therapy. Additionally, immunotherapies may have long-lasting anti-cancer benefits even after treatment has been completed. If you've been diagnosed with lung cancer, it's important to discuss all available treatment options with your doctor. While immunotherapy offers many advantages, it's not suitable for everyone and may have some risks associated with it. #LungCancer #LungCancerAwarenessMonth